TAS0612, a novel and highly potent RSK, AKT, and S6K inhibitor, exhibited strong antitumor effect in preclinical tumor models with deregulated RAS and PI3K pathway activities
EUROPEAN JOURNAL OF CANCER（2018）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要